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Abstract 
Osteosarcoma (OSA) is a rare cancer in people. However OSA incidence rates in dogs are 27 times higher than in 
people. Prognosis in both species is relatively poor, with 5 year OSA survival rates in people not having improved in 
decades. For dogs, 1 year survival rates are only around ~ 45%. Improved and novel treatment regimens are urgently 
required to improve survival in both humans and dogs with OSA. Utilising information from genetic studies could 
assist in this in both species, with the higher incidence rates in dogs contributing to the dog population being a good 
model of human disease. This review compares the clinical characteristics, gross morphology and histopathology, 
aetiology, epidemiology, and genetics of canine and human OSA. Finally, the current position of canine OSA genetic 
research is discussed and areas for additional work within the canine population are identified.
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Background
Cancer is a leading cause of non-communicable morbid-
ity and mortality throughout the world, second only to 
cardiovascular disease in the number of deaths of adults 
between the ages of 30 and 70 years old [1, 2]. For dogs, 
the most frequent causes of mortality in order are (i) 
cancer, (ii) trauma, (iii) locomotor (skeletal, muscles and 
joints), (iv) cardiac disease, and (v) neurological disease 
[3]. The development of new and superior cancer treat-
ments has long been a priority in medicine, more recently 
there has been a drive to develop new approaches to treat 
and manage cancer in companion animals. Indeed, can-
cer in dogs is increasingly a concern for pet owners, in 
particular as some types of cancer occur at much higher 
rates in certain dogs breeds [4–7]. These cases of cancer 
in dogs themselves require treatment, in addition these 
spontaneous cancers in dogs represent effective models 
for the human disease equivalent [8]. Although devel-
oping new treatments in companion animals with natu-
rally occurring disease is less contentious than inducing 
disease in experimental animals, ethical concerns with 
regards to the treatment of individuals enrolled on stud-
ies and gaining informed consent from owners remain 
[9].
Cancer is more common in adults than children, 
adolescents, and young adults (<  30  years old) [10, 11]. 
Despite this, bone cancer is most common in the young 
(< 20 years old) and elderly (over 60 years old) than indi-
viduals of intermediary age (20–60  years old) [10–12]. 
For many cancer types 5 year survival rates are improv-
ing, reflecting the development of earlier diagnostic tech-
niques and improved treatments [1, 13]. In contrast to 
many other cancers OSA, the most common bone cancer, 
has not shown comparable improvements in mortality 
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rates [13–15]. There is thus an urgent need to develop 
improved treatments for OSA.
In both human and canine patients the predominant 
bone cancer diagnosis is OSA [15, 16]. OSA is still con-
sidered rare in humans. For example, there were 217,440 
estimated breast cancer cases in the NIH–NCI surveil-
lance, epidemiology, evidence and end results (SEER) 
database in 2004 alone, compared to 3482 cases of OSA 
in the same database between 1973 and 2004 [15, 17]. 
Although OSA is also not very common in dogs, it is 
much more common than in people. Norwegian owner 
questionnaire data from four breeds (Labrador retriever, 
Newfoundland, Leonberger and Irish wolfhound) showed 
OSA incidences of between 0.2 and 8.9% depending on 
the breed [18]. The percentage of dogs positively identi-
fied with OSA in two Polish clinics was estimated to be 
between 2.7 and 10.7%, again depending on breed [19]. 
Between 1995 and 2002 of 394,061 insured Swedish dogs, 
764 (0.19%) developed a bone cancer [16]. This is an 
incidence rate of 27.2 dogs per 100,000 included in the 
dataset each year. While the canine data only includes 
insured dogs, it is a large dataset so is likely to be repre-
sentative of the dog population of the country as whole. 
In the comparable Swedish population, 234 men and 164 
women had bone cancer between 1998 and 2002, which 
is roughly 0.89 cases of bone cancer per 100,000 people 
each year [11]. The human data records all bone can-
cer cases in the country and the average population size 
between 1998 and 2002 was calculated from government 
census data. In addition all other countries in the “Can-
cer Incidence in Five Continents” registry report human 
incidence rates similar to Sweden [11, 12]. Thus, the inci-
dence of canine bone cancer is 27 times higher than in 
humans. The higher incidence rate of canine OSA makes 
the pet dog population a good model for human disease. 
While there is potential for any dog to develop OSA, a 
subset of larger dog breeds are at increased risk of devel-
oping OSA [16].
The purpose of this review is to give an insight into the 
morphology, epidemiology, prognosis, treatment and 
genetics of osteosarcoma and to compare these aspects, 
in light of the published literature, between humans and 
dogs. Such knowledge is required to translate advances 
made in the clinical management of OSA in people to 
dogs; and to advance our understanding of where disease 
processes are similar across species.
Search strategy
This review is based on a search in PubMed (http://www.
ncbi.nlm.nih.gov/pubmed) using the terms “canine, dog, 
human, osteosarcoma, cancer, tumour, oncology”. Each 
title and abstract of the obtained hits were evaluated and 
articles referring to genetics, epidemiology, treatment, 
histology and prognosis were assessed in detail (full text). 
Searches were carried out from 06/2016 to 02/2017 an 
additionally 08/2017. All titles, abstracts and full texts 
were read and obtained by all authors. Searches included 
web of science and PubMed. All papers published prior 
to, and including 08/2017 were included. Our personal 
photograph archives were used to illustrate OSA (with 
appropriate ethical permissions) and our experience 
within the field was used to evaluate the literature.
Gross and histological similarities and differences 
between canine and human OSA
A sarcoma is a malignant tumour originating in tissues 
derived from the mesoderm; affecting bone, cartilage and 
other connective tissues [20]. OSA is a sarcoma which 
produces bone or osteoid [21]. In both people and dogs, 
the gross appearance of the OSA is markedly variable, 
some being predominantly lytic (soft, fleshy and with 
areas of haemorrhage and necrosis), productive (hard 
consistency and variably grey in colour), or being a mix 
of both. It frequently transgresses the cortex at the same 
time that it grows within the medulla, rarely penetrating 
the joint (Fig. 1) [22]. World Health Organisation (WHO) 
defines OSA as a primary malignant bone tumour in 
which the neoplastic cells produce osteoid [22]. In both 
people and dogs, OSA is characterized by a highly pleo-
morphic and heterogeneous microscopic appearance, 
and it is divided into several histologic subtypes simi-
lar in both species (Table  1) [22, 23]. Commonly, these 
subtypes are typically mixed in the same tumour, which 
questions the significance of histologic tumour classifi-
cation for prognostic purposes. Indeed, histologic sub-
type could not be demonstrated to influence biological 
Fig. 1 Femoral osteosarcoma. Greyhound, 7 years and 7 months old. 
Dense sclerotic neoplastic proliferation with hard consistency at the 
level of the proximal metaphysis. The tumour infiltrates the medullary 
cavity and transgresses the cortical bone
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tumour behavior in dogs [24] and is controversially dis-
cussed in human literature. The most common subtype 
is the osteoblastic form in both people and dogs (Fig. 2) 
[21, 25, 26]. Furthermore, OSAs are classified on tumour 
grade, which is based on microscopic features such as 
cellular pleomorphism, mitotic index, tumour matrix and 
degree of necrosis [25–27]. The vast majority of canine 
and human OSAs are high grade tumours [21, 26, 28]. 
Regarding the prognostic effect of OSA grading, the vet-
erinary literature remains divided [26, 29, 30], whereas 
it is considered important and relevant for prognosis in 
human medicine [27].
The vast majority of OSAs in both dogs and humans 
arise from within bones, particularly in the metaphyseal 
regions of long bones [22, 23] but can also originate on 
the surface of the bone or be extra-osseous [21]. In both 
humans and large dogs, OSA has a clear preference for 
the appendicular skeleton (up to 80% in dogs and 90% in 
humans) over the axial skeleton, with different bone per-
centages of involvement associated to the main weight 
bearing regions in each species. In people, ~ 50% of cases 
occur in the region of the knee (distal femur > proximal 
tibia followed by proximal humerus in approximately 
25% of cases), in dogs the forelimbs are affected twice as 
often as the hind limbs (mainly distal radius and proxi-
mal humerus followed by distal and proximal femur and 
distal tibia) [31].
Treatment of osteosarcoma in humans and dogs
In both humans and dogs, treatment for OSA involves 
surgery to remove primary tumours and on occasion 
distant metastasis, combined with neoadjuvant and/or 
adjuvant chemotherapy [32, 33]. Surgery involves either 
amputation of the limb or limb salvage/sparing pro-
cedures [34, 35]. Limb salvage is most frequently per-
formed on patients with lower grade tumours and has 
been associated with similar outcomes to conventional 
approaches using amputation [35]. The proposed advan-
tage of limb salvage surgery over amputation is that 
these patients have a better return-to-function and con-
sequently quality-of-life than those undergoing amputa-
tion [36]. A recent meta-analysis supported this benefit 
in addition to a lower incidence of metastasis with limb 
salvage [37]. Similar advantages have yet to be reported 
in dogs undergoing limb salvage, perhaps suggesting 
poor cross-species efficacy. Canine reports suggest a 
similar metastatic frequency and survival time with limb 
salvage compared with the more conventional approach 
of amputation and adjuvant chemotherapy [38]. The fail-
ure to identify a significant difference in the outcomes 
in dogs compared with humans may be related to fewer 
numbers of dogs undergoing limb salvage procedures 
and therefore a more limited experience with the proce-
dure. It is also possible that differences in case selection 
between humans and dogs impacts on outcome, in dogs 
clearly this may be the result of both patient factors and 
owner factors. Until a greater number of cases appear 
in the canine literature, the reason for the differences in 
outcomes remains unclear. Of note however from the 
canine literature on limb salvage, is that post-operative 
infections are associated with increased survival times 
[39–42]. The mechanism responsible for this prolonged 
survival and disease-free interval has yet to be elucidated, 
but is hypothesised to be due to up-regulation of antitu-
mor immunity [39]. This is phenomenon is not unique 
Table 1 Histologic subtypes of  human and  canine osteo-
sarcoma
a Based on World Health Organization (WHO) International Histological 
Classification of Tumors of Domestic Animals [23]
b Based on WHO Classification of Tumours of Bone [22]
Species Caninea Humanb
Subtypes A. Central Osteosarcoma
 Osteosarcoma Low‑grade central osteo‑
sarcoma
 a. Poorly differentiated Conventional
 b. Osteoblastic  Chondroblastic
  Nonproductive  Fibroblastic
  Productive  Osteoblastic
 c. Chondroblastic  Secondary
 d. Fibroblastic Telangiectatic
 e. Telangiectatic Small cell
 f. Giant cell type Parosteal
B. Peripheral Periosteal
 1. Periosteal osteosarcoma High grade surface
 2. Parosteal osteosarcoma
Fig. 2 Microphotograph of a productive osteoblastic osteosarcoma. 
Abundant accumulation of extracellular lakes of osteoid between 
malignant osteoblasts. Haematoxylin and eosin stain. Obj. 20x
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to the dog and has also been reported in humans, with a 
similarly unclear aetiology [43, 44].
In human OSA, surgery with adjuvant chemotherapy 
remains the treatment of choice [45, 46]. The standard 
adjuvant chemotherapeutic approach uses a combina-
tion of methotrexate, doxorubicin and cisplatin using 
either a high, moderate, or standard dose protocols 
[47–50]. This approach has remained relatively unaltered 
for many years. The inclusion of additional chemothera-
peutics including ifosfamide has met with mixed results 
and meta-analyses have provided conflicting evidence as 
to whether this provides a clear benefit in all cases [51, 
52]. Whilst a large number of protocol modifications 
and experimental therapies have been reported, these at 
present do not offer credible therapeutic alternatives to 
improve outcome in affected individuals [49]. However 
there is evidence suggesting six doses of carboplatin may 
be superior to alternating doxorubicin and carboplatin 
regimens [53]. In canine OSA adjuvant chemotherapy 
with either doxorubicin or the platinum-based com-
pounds including cisplatin and carboplatin have been 
associated with increased survival times over amputation 
alone [54–57]. The relative merits of the individual chem-
otherapy drugs have been evaluated. Reports indicate no 
significant difference in disease free interval or survival 
times in those dogs receiving either post-operative doxo-
rubicin or carboplatin or combinations thereof for OSA 
[32]. However, those dogs receiving carboplatin experi-
enced fewer side-effects improving the quality of life dur-
ing therapy, an important consideration for most owners. 
Combination protocols with doxorubicin and carbopl-
atin have also been evaluated for their potential benefit 
in improving disease free interval and survival times [58]. 
This combination protocol has been associated with a 
greater degree of chemotherapy induced toxicity [59]. A 
recent prospective study comparing carboplatin with an 
alternating carboplatin-doxorubicin protocol showed no 
benefit of the combination in improving survival over 
carboplatin alone [53]. Other (retrospective) publica-
tions using this combination have failed to demonstrate 
a clear benefit over single-agent carboplatin [58, 59]. 
Limited publications exist evaluating the benefits of addi-
tional chemotherapeutic agents for canine OSA e.g. gem-
citabine; none provide a clear improvement in outcome 
above the use of carboplatin [60].
The use of bisphosphonate therapy as an adjunct to 
standard approaches for treating OSA has received rea-
sonable coverage in the literature. A wide variety of 
experimental data exists on their efficacy in vitro and in 
models of OSA [61–65]. There has however been equivo-
cal clinical benefit from their use in both in vivo models 
and in naturally occurring disease [66–68]. Whilst their 
value in management of the primary disease is unclear, 
perhaps more compelling evidence exists for their role in 
managing metastatic disease [63, 69–71]. This is a very 
important feature in managing OSA, given the impor-
tance of metastatic disease in overall mortality.
More recent reports on the use of immunotherapy 
based on an attenuated recombinant Listeria monocyo-
togenes expressing a chimeric HERS/neu fusion protein 
have shown some encouraging results [72]. Dogs having 
undergone surgery (with amputation or limb salvage) 
with post-operative chemotherapy with four doses of 
carboplatin were enrolled in this study. In these dogs, 
3  weeks after completion of their chemotherapy proto-
col they received the immunotherapy agent. There was 
an overall increase in survival time and reduction in the 
incidence of metastasis compared with historic controls. 
Newer therapeutic treatments including immunothera-
pies are also being investigated and developed in peo-
ple given the failure to improve the outcome of human 
patients significantly in the past 30 years [73–75].
Given the failure to significantly improve the treatment 
approach and therefore outcome of OSA in humans over 
the past 3 decades [76, 77] and in dogs over the same 
period [78–80], novel approaches are clearly required. 
One particular area of medicine that may provide 
improved treatment approaches for OSA focuses on the 
field of pharmacogenomics. Here specific pharmacoge-
netic biomarkers and targets can provide a personalised 
approach to therapy for OSA [81, 82]. This approach 
whilst desirable remains in its infancy but clearly pro-
vides exciting potential for future management of OSA in 
both humans and dogs.
Prognostic factors for osteosarcoma in humans 
and dogs
Key factors affecting treatment outcome are diagnos-
tic and prognostic tools. Typical OSA disease progres-
sion consists of a primary tumour, usually originating 
within the medullary cavity, which grows, proliferates, 
and invades, and left unchecked frequently metastasises 
to the lungs [83]. Prognosis for individuals with meta-
static tumours is much poorer than for individuals with 
only primary tumours. The 5-year-event-free-survival for 
humans with metastatic tumours at diagnosis reported to 
be 27.4%, while individuals with no metastases at diagno-
sis the 5-year-event-free-survival is ~  70% [15, 83]. The 
prognosis for canine OSA is poor with 1  year survival 
rates following diagnosis and treatment typically less 
than 45% [84–86]. Of those dogs surviving beyond 1 year, 
~  54% will develop metastatic disease with a median 
survival time of 243 days [40]. In dogs with evidence for 
metastatic disease at the time of diagnosis, the median 
survival time is 76 days [23]. There is gathering evidence 
in some cases (although limited by study numbers) that 
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in addition to the understanding that certain breeds are 
predisposed to developing OSA, there are also specific 
genetic differences within the tumours encountered in 
certain breeds which may have prognostic significance 
[87, 88].
A number of factors have been suggested to have 
prognostic significance in canine OSA. Bodyweight and 
tumour location have been suggested to be of particular 
importance and are readily available parameters for all 
patients. Dogs with lower body weight have a longer sur-
vival time [39, 89, 90] and dogs with proximal humeral 
tumours experience a shorter survival time [91]. Serum 
biomarkers have also been evaluated, such markers are 
clearly desirable particularly if routinely measured as this 
helps clinicians to begin discussions around prognosis 
with clients without recourse to advanced diagnostics. 
Increased serum alkaline phosphatase activity in dogs 
has been associated with a shorter disease free interval 
and survival time [92]. Histological grading is relevant 
for prognosis in human medicine [27], but remains con-
troversial in dogs [26, 29, 30]. A recent meta-analysis in 
dogs has suggested that ALP and a proximal humeral 
location are significant negative prognostic factors. The 
importance of other factors was difficult to determine 
in this meta-analysis due to limited numbers of dogs 
and studies in which these had been reviewed [91]. In 
humans, the extent of any histological response to pre-
operative chemotherapy has significant predictive value 
for both local and distant disease control [48, 77]. A simi-
lar effect has not been reported in dogs, this may be due 
to pre-operative chemotherapy not being part of routine 
treatment for canine OSA. In both humans and dogs 
molecular and genetic factors have also been identified as 
having potential prognostic significance. Many of these 
have been identified in OSA cell lines and therefore their 
clinical significance needs clarifying, however a num-
ber of cell lines have shown similarities between human 
and canine OSA, these therefore represent a very valu-
able evaluation tool [93]. Some of the factors observed in 
cell lines include HER-2 and PTEN, which have also been 
identified in some tissue samples [31]. The expression of 
matrix metalloproteases have also been demonstrated 
in some tissue samples (MMPs 2 and 9), however the 
clinical and prognostic significance of these is unclear. 
In humans, the literature often has conflicting data on 
the significance of particular markers. For example, the 
human epidermal growth factor 2 oncogene (HER-2) 
has been suggested in some reports to have prognostic 
significance, though further study is required to defini-
tively confirm this [94–96]. Epidermal growth factor 
has been evaluated in dogs, whilst expressed in primary 
and metastatic tumour cells, it has not been shown to be 
an effective prognostic marker clinically [97]. Vascular 
endothelial growth factor A (VEGFA) has also been 
implicated in prognosis and over-expression has been 
associated with shorter survival times in humans [98]. 
However, at present the actual value of VEGFA in prog-
nostication remains to be clarified [98, 99]. In humans 
p53 has been shown to be an effective prognostic marker 
and upregulated p53 is associated with a shorter survival 
time [100]. This has also been associated with prognosis 
canine OSA [101]. Strong expression of CXCL-12 is also 
associated with a more favourable outcome in humans 
with OSA [96]. The significance of CXCL-12 expression 
has yet to be investigated in dogs. MicroRNA transcripts 
have also been investigated for their prognostic sig-
nificance. It would seem that down-regulation of 14q32 
miRNA expression is a conserved mechanism in both 
human and canine OSA samples and influences tumour 
behaviour [102]. One particularly promising molecule 
however is ezrin, a membrane cytoskeleton linking mol-
ecule. This has been associated with a shorted survival 
time in both humans and dogs with OSA [103–106]. In 
addition to overall prognosis, a number of factors have 
been implicated in the development of metastatic dis-
ease. Given that local disease control is not the major 
life-limiting aspect to both canine and human OSA, iden-
tifying factors affecting metastasis are crucial. A num-
ber of markers have been identified in humans including 
Hes4 [107] and in canine OSA the proto-oncogene c-Met 
has been implicated in lymphatic spread [108].
Epidemiology and genetics of osteosarcoma 
in humans
Some cases of human OSA are associated with heritable 
cancer syndromes, and the genetic bases of these have 
been established [109–111]. Most instances of OSA, 
however are not associated with heritable cancer syn-
dromes and there have only been two heritable genetic 
loci identified, but there are some risk factors associated 
with OSA development including growth, puberty, sex, 
and race [15, 112, 113]. Evidence that growth plays a part 
in the development of OSA comes from the age of onset 
frequently coinciding with rapid bone growth during 
puberty, tumour sites most frequently at the end of bones 
where active growth occurs, and people affected by OSA 
are on average taller than the unaffected population [15, 
112]. There is a difference between sexes in the devel-
opment of OSA with males more commonly affected 
than females, and there is some evidence of variation in 
the incidence rate between races in the USA [15, 112]. 
Although OSA itself does not appear to be directly herit-
able in most instances, there are heritable components to 
the risk factors [114].
There have been somatic mutations in tumour sup-
pressor genes identified in individuals with heritable 
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cancer syndromes, and there have been mutations iden-
tified in OSA tumours compared to non-tumours [109, 
115–117]. There have, however, only been two somatic 
genetic mutations associated with OSA specifically [113]. 
This lack of identified somatic genetic associations is not 
surprising based on the lack of heritability observed in 
human OSA. Despite the lack of heritability and somatic 
genetic mutations identified there have been over 900 
genes associated with human OSA [118]. These genes 
have been associated with OSA due to either differences 
in expression between tumour and non-tumour tissue, 
or due to mutations that have arisen in the tumour tissue 
compared to the non-tumour tissue [119–121]. Muta-
tions in OSA tumour tissue, but not non-tumour tis-
sue, and differences in gene expression between tumour 
and non-tumour tissue could be either the cause of the 
tumour or a result of the tumour. A possible cause of 
both differences in expression between tumour and 
non-tumour tissue, and mutations in tumour but not 
non-tumour tissue, is genomic and chromosomal insta-
bility [122, 123]. Genomic and chromosomal instability 
is a reported factor in many types of cancer progression 
[122, 123]. OSA has been shown to display chromosomal 
instability associated with mutations in the TP53 gene 
[124]. A consequence of this chromosomal instability is 
aneuploidy, which can lead to the overexpression of some 
genes within malignant cells, disrupting normal cell pro-
cesses [125]. Although mutations in TP53 appear to be 
associated with chromosomal instability, the gene itself 
does not seem to be subsequently over expressed follow-
ing aneuploidy [124, 125].
Epidemiology and genetics of osteosarcoma 
in dogs
As outlined above, canine OSA is more common than 
human OSA [11, 12, 16]. Despite this there are similar 
risk factors associated with the development of OSA in 
dogs as in people, including growth and sex [16, 126]. 
In addition, OSA in dogs is also influenced by breed 
and neutering status [16, 126]. Large dogs constitute the 
majority of OSA cases [16, 94]. Similarly, people with 
OSA are commonly taller than average [112]. In the 
canine population, as with the human population, there 
also appears to be a sex disparity, with males more likely 
to develop OSA than females [12, 16]. Neutering status, 
although not relevant in the human context, appears to 
contribute to OSA risk where neutered dogs are more 
likely to develop OSA than non-neutered dogs [126]. 
This, combined with the association with puberty, sug-
gests a complex role for sex hormone signalling in OSA 
risk. In contrast to human OSA, canine OSA appears to 
be heritable, with some breeds appearing to be predis-
posed to developing OSA compared to others [16, 127]. 
Interestingly of the 15 breeds with the highest reported 
incidence of OSA 12 are within a clear clade on the 
canine phylogeny [16, 128]. This relationship between 
affected breeds could indicate a potential common 
genetic origin of canine OSA across breeds, however 
the clade is large and contains many breeds that are not 
highly affected by OSA, thus this seems less likely [128].
Four breeds of dog that have a high incidence of OSA 
are the Rottweiler, Greyhound, Deerhound and Irish 
Wolfhound. The Irish Wolfhound, the largest breed, has 
the highest prevalence of OSA within the insured Swed-
ish dog population once numbers within the population 
are taken into account [16]. It also has one of the lower 
median ages of onset at 6.6 years, only the greyhound has 
a lower median age of onset at 6.2 years [16]. Greyhounds 
are recognised to frequently develop OSA—accounting 
for around 25% of mortality in some cohorts [129, 130]. 
Although The Irish Wolfhound history includes a period 
when they were close to extinction [131]. In the process 
of conserving the breed the few remaining Irish Wolf-
hounds were crossed with Great Danes, Deerhounds, 
Borzois, and Mastiffs [131, 132]. This out-crossing will 
have introduced some genetic diversity, but to retain the 
Irish Wolfhound phenotype a large amount of inbreeding 
will have been required, therefore as with most modern 
breeds, genetic diversity is low within the breed [133]. 
Importantly for the Irish Wolfhound breed both Great 
Danes and Deerhounds have a high prevalence of OSA, 
and these were two breeds used to help rescue Irish Wolf-
hounds from extinction [16, 127, 131]. Combined with 
inbreeding, the use of two breeds predisposed to devel-
oping OSA could have led to Irish Wolfhounds acquiring 
OSA predisposition genes from both breeds. The Deer-
hound, a hunting dog, with references as far back as the 
third century; was split into various strains in the early 
nineteenth century, which is likely to have had an effect 
on genetic diversity. The Rottweiler is also a large breed 
of dog and within the insured Swedish dog population 
they have the 5th highest incidence ranking (after correc-
tion for actual numbers of dogs) for OSA with a median 
age of onset of 7.9 years [16]. The Rottweiler originated 
in Germany being used for guarding, droving, and as a 
draught dog [134]. Following the creation of breed stand-
ards in the 1930s, when the breed was registered with the 
UK and American Kennel Clubs it is likely that Rottweil-
ers have exclusively been mated with other Rottweilers 
leading to a closed gene pool within the pedigree Rott-
weiler population [134, 135].
There have been 34 genetic loci associated with canine 
OSA across four breeds [136, 137]. One study identi-
fied 33 loci as associated with canine OSA across three 
breeds [136] and another identified a single locus asso-
ciated with OSA in Deerhounds [137]. None of the loci 
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were consistently associated across breeds, further sug-
gesting that there may be a difference between breeds 
in the genetic predisposition to developing canine OSA 
[136, 137]. There have been 4 loci associated with the 
development of OSA in Irish Wolfhounds [136]. In Rot-
tweilers 15 loci were associated with the development 
of OSA [136]. Deerhounds also have a high prevalence 
of OSA with an incidence rate of 15% and a heritabil-
ity value of 0.69 [126, 127]. Those Deerhounds carrying 
putative high-risk dominant allele are considered to have 
a >  75% risk of developing OSA compared with those 
not carrying the allele. This has been mapped to CFA34 
[137]. Unusually, in this breed, females appear to have an 
increased risk of developing OSA; this is not influenced 
by the neuter status [127]. Genetic analysis of Grey-
hounds has shown 14 inherited risk loci, the strongest 
in this breed was located 150 kb upstream of the tumour 
suppressor genes CDKN2A/B [136]. Interestingly the risk 
of developing OSA seems not to be a general feature of 
derivative breeds such as Whippets. Despite close clus-
tering of molecular microsatellite markers, Whippets 
rarely suffer from OSA [138]. This raises the question of 
whether genetic factors alone account for the incidence 
of OSA in this breed. The influence of IGF-1 on size vari-
ation in dogs may have an influence in this regard, given 
the possible association with the development of canine 
OSA [139].
Currently none of the genetic variants identified as 
associated with canine OSA have been mechanisti-
cally verified. Verification of the mode of action could 
lead to the identification of novel therapeutic targets, 
and if these loci can be shown to consistently predict an 
increased risk of OSA, the number of affected individu-
als could be reduced. Breeders could genotype prospec-
tive sires and dams prior to mating and choose parents 
to reduce the risk of offspring having multiple deleterious 
OSA alleles in conjunction with minimising the epide-
miological factors. In addition to the 34 genetic loci iden-
tified as associated with canine OSA, there have been 
genes identified as differentially expressed in canine OSA 
compared to non-tumour tissue that have implications 
for growth and metastasis, and are potential drug tar-
gets [140–143]. These genes have been identified utilis-
ing canine OSA tumour tissue, and canine OSA cell lines. 
There has also been variation in the expression of genes 
within tumours associated with survival time in canine 
OSA [97, 144–146].
Conclusions
There are several dog breeds that appear to have a genetic 
predisposition to OSA for which no OSA associated loci 
have been identified, these breeds could benefit from 
the identification of OSA predisposition loci. Additional 
work is required to confirm the effect of the genetic loci 
identified as associated with canine OSA, and account 
for the variation observed in the development of disease. 
This is also the case with humans, therefore comparing 
the two species may provide valuable insights into dis-
ease origins and progression, given the many similarities 
between the tumour in both species. Further work is also 
required to establish improved treatment regimens for 
individuals that develop disease, the identification of par-
ticular genetic pathways that are altered in OSA tumour 
tissue compared to non-tumour tissue could facilitate 
this. Any genetic loci identified as associated with canine 
OSA have the potential to be examined for an association 
with human OSA, and any treatments shown to be effec-
tive in either species could be applied to the other.
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